Adult mesenchymal stem cells are being tested in clinical trials in MS. A person’s own mesenchymal stem cells are isolated from the bone marrow or blood stream and multiplied in the lab, and then re-introduced in greater numbers into their body. Alternatively, the cells are sometimes treated prior to transfer to potentially enhance their ability to suppress nervous system-damaging immune responses and/or promote myelin repair.
Only when the results of clinical trials are available will it be possible to determine what the optimal cells, delivery methods, safety and actual effectiveness of this experimental approach might be for people with MS.
Mesenchymal stem cells are being tested in several clinical trials including:
• Results were reported
from a phase 2 open-label study of repeated intrathecal administration of NurOwn®
(Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors, MSC-NTF) at Cleveland Clinic and Stanford University in 18 people with progressive MS. The study is being sponsored by BrainStorm Cell Therapeutics Inc. The cells were derived from individuals’ own bone marrow (mesenchymal) stem cells, which were treated in the laboratory to encourage them to secrete neuroprotective factors. The participants then received three separate cell injections into the spinal canal every two months. The treatment appeared to be safe, and there also appeared to be some improvements in cognition, vision, mobility, and other functions by comparing participants with those involved in other studies. Read the ECTRIMS abstract
• Results were published
from a Hadassah University Hospital phase 2 clinical trial to establish the optimal way to administer mesenchymal stem cells in active, progressive MS. Participants are people with progressive MS with moderate to more severe disability. They administered the cells into the vein or the spinal fluid and then monitoring patients with various measures to try to detect a benefit and to find the best route for administering these cells. Most participants stabilized, and some showed improvement. Read more
• Results were published
from the international MESEMS trial, a phase 2 clinical trial conducted at 15 sites in 9 countries, testing the ability of mesenchymal stem cells to reduce new inflammation seen on MRI brain scans of people with relapsing MS, 24 weeks after one dose of participants’ own cells were infused into their veins. The procedure was found to be safe, but it did not reduce the risk of active brain lesions, which was the main endpoint established for this trial. Read more
• Results were published
in February 2018 from a small, open label, phase 1 stem cell trial at the Tisch MS Research Center of New York. This trial used 20 individuals’own mesenchymal stem cells to derive more specific stem cells called “neural progenitor cells.” The cells were expanded in the laboratory and then injected into the space around the spinal cord (intrathecal). The goal was to inhibit immune mechanisms and to augment tissue repair.
The team reported mild to moderate headache and fever as the most common side effects, and for the primary outcome of the study, which was safety, they reported no serious adverse events. Although the study was not designed to determine potential benefits of this therapy, the team reported clinical observations including some improvements in EDSS scores, strength in some muscle groups, walking speeds and bladder symptoms. Larger, longer-term, controlled studies are needed to determine the safety and effectiveness of using this approach to treat MS.
The Tisch Center team has launched a phase II trial of this therapy. The National MS Society has agreed to partially support this trial of intrathecal stem cells in progressive MS. This trial is ongoing
• A phase 1/2 clinical trial is testing IV infusion of participants’ own mesenchymal cells. The trial involves 30 people with active MS, and is taking place at three sites in Spain: University Hospital Reina Sofia in Córdoba, University Regional Hospital Carlos Haya in Málaga, and University Hospital Virgen Macarena in Sevilla. This trial is ongoing
• A small, open-label, phase 1 clinical trial
at Cleveland Clinic tested the ability of an individual’s own mesenchymal stem cells to both inhibit immune mechanisms and to augment intrinsic tissue repair processes in people with relapsing forms of MS. They were given intravenously (infused into the vein). This study was led by Dr. Jeffrey A. Cohen and supported by the Congressionally Directed Medical Research Programs. The National MS Society provided support for a pilot study related to this trial to compare stem cells from people with MS and controls without MS, looking at how the cells survive and function, to enhance understanding from this stem cell trial. This trial, which was designed to evaluate safety and not designed to determine benefits, was completed and preliminary results were published
in April 2017, suggesting that this approach was safe and warrants longer, larger trials.
• A Phase 1 trial allogenic human neural stem cells in secondary progressive MS is underway in Italy and Switzerland. The trial is testing four different dosages injected into the brain. This trial is completed
Larger, longer-term, controlled studies are needed to determine the safety and effectiveness of using stem cells to treat MS. When the results of these and subsequent clinical trials are available, it should be possible to determine what the optimal cells, delivery methods, safety and actual effectiveness of these current experimental therapies might be for different people with MS.
Read more about stem cell clinics.